vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and VISHAY INTERTECHNOLOGY INC (VSH). Click either name above to swap in a different company.

VISHAY INTERTECHNOLOGY INC is the larger business by last-quarter revenue ($800.9M vs $487.7M, roughly 1.6× CLOVER HEALTH INVESTMENTS, CORP.). VISHAY INTERTECHNOLOGY INC runs the higher net margin — 0.1% vs -10.1%, a 10.2% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 12.1%). VISHAY INTERTECHNOLOGY INC produced more free cash flow last quarter ($54.6M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 3.6%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Vishay Intertechnology, Inc. is an American manufacturer of discrete semiconductors and passive electronic components founded by Polish-born businessman Felix Zandman. Vishay has manufacturing plants in Israel, Asia, Europe, and the Americas where it produces rectifiers, diodes, MOSFETs, optoelectronics, selected integrated circuits, resistors, capacitors, and inductors. Vishay Intertechnology revenues for 2024 were $2.9 billion. At the end of 2024, Vishay had approximately 22,700 full-time e...

CLOV vs VSH — Head-to-Head

Bigger by revenue
VSH
VSH
1.6× larger
VSH
$800.9M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+32.7% gap
CLOV
44.7%
12.1%
VSH
Higher net margin
VSH
VSH
10.2% more per $
VSH
0.1%
-10.1%
CLOV
More free cash flow
VSH
VSH
$123.5M more FCF
VSH
$54.6M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
3.6%
VSH

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
VSH
VSH
Revenue
$487.7M
$800.9M
Net Profit
$-49.3M
$986.0K
Gross Margin
19.6%
Operating Margin
-10.1%
1.8%
Net Margin
-10.1%
0.1%
Revenue YoY
44.7%
12.1%
Net Profit YoY
-123.2%
101.5%
EPS (diluted)
$0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
VSH
VSH
Q4 25
$487.7M
$800.9M
Q3 25
$496.6M
$790.6M
Q2 25
$477.6M
$762.3M
Q1 25
$462.3M
$715.2M
Q4 24
$337.0M
$714.7M
Q3 24
$331.0M
$735.4M
Q2 24
$356.3M
$741.2M
Q1 24
$346.9M
$746.3M
Net Profit
CLOV
CLOV
VSH
VSH
Q4 25
$-49.3M
$986.0K
Q3 25
$-24.4M
$-7.9M
Q2 25
$-10.6M
$2.0M
Q1 25
$-1.3M
$-4.1M
Q4 24
$-22.1M
$-66.1M
Q3 24
$-9.2M
$-19.3M
Q2 24
$7.4M
$23.5M
Q1 24
$-19.2M
$30.9M
Gross Margin
CLOV
CLOV
VSH
VSH
Q4 25
19.6%
Q3 25
19.5%
Q2 25
19.5%
Q1 25
19.0%
Q4 24
19.9%
Q3 24
24.5%
20.5%
Q2 24
30.3%
22.0%
Q1 24
23.6%
22.8%
Operating Margin
CLOV
CLOV
VSH
VSH
Q4 25
-10.1%
1.8%
Q3 25
-4.9%
2.4%
Q2 25
-2.2%
2.9%
Q1 25
-0.3%
0.1%
Q4 24
-6.4%
-7.9%
Q3 24
-2.7%
-2.5%
Q2 24
2.0%
5.1%
Q1 24
-6.5%
5.7%
Net Margin
CLOV
CLOV
VSH
VSH
Q4 25
-10.1%
0.1%
Q3 25
-4.9%
-1.0%
Q2 25
-2.2%
0.3%
Q1 25
-0.3%
-0.6%
Q4 24
-6.6%
-9.2%
Q3 24
-2.8%
-2.6%
Q2 24
2.1%
3.2%
Q1 24
-5.5%
4.1%
EPS (diluted)
CLOV
CLOV
VSH
VSH
Q4 25
$0.01
Q3 25
$-0.06
Q2 25
$0.01
Q1 25
$-0.03
Q4 24
$-0.48
Q3 24
$-0.14
Q2 24
$0.17
Q1 24
$0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
VSH
VSH
Cash + ST InvestmentsLiquidity on hand
$78.3M
$515.0M
Total DebtLower is stronger
$950.9M
Stockholders' EquityBook value
$308.7M
$2.1B
Total Assets
$541.0M
$4.2B
Debt / EquityLower = less leverage
0.46×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
VSH
VSH
Q4 25
$78.3M
$515.0M
Q3 25
$443.9M
Q2 25
$473.9M
Q1 25
$609.4M
Q4 24
$194.5M
$590.3M
Q3 24
$288.0M
$643.8M
Q2 24
$254.8M
$672.7M
Q1 24
$208.3M
$796.5M
Total Debt
CLOV
CLOV
VSH
VSH
Q4 25
$950.9M
Q3 25
$919.7M
Q2 25
$914.5M
Q1 25
$988.2M
Q4 24
$905.0M
Q3 24
$820.8M
Q2 24
$820.6M
Q1 24
$819.4M
Stockholders' Equity
CLOV
CLOV
VSH
VSH
Q4 25
$308.7M
$2.1B
Q3 25
$340.9M
$2.1B
Q2 25
$344.2M
$2.1B
Q1 25
$336.1M
$2.0B
Q4 24
$341.1M
$2.0B
Q3 24
$342.2M
$2.2B
Q2 24
$324.9M
$2.2B
Q1 24
$292.5M
$2.2B
Total Assets
CLOV
CLOV
VSH
VSH
Q4 25
$541.0M
$4.2B
Q3 25
$559.7M
$4.2B
Q2 25
$575.0M
$4.2B
Q1 25
$583.7M
$4.2B
Q4 24
$580.7M
$4.1B
Q3 24
$653.0M
$4.2B
Q2 24
$674.2M
$4.2B
Q1 24
$671.8M
$4.3B
Debt / Equity
CLOV
CLOV
VSH
VSH
Q4 25
0.46×
Q3 25
0.44×
Q2 25
0.44×
Q1 25
0.49×
Q4 24
0.45×
Q3 24
0.38×
Q2 24
0.38×
Q1 24
0.38×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
VSH
VSH
Operating Cash FlowLast quarter
$-66.9M
$149.4M
Free Cash FlowOCF − Capex
$-69.0M
$54.6M
FCF MarginFCF / Revenue
-14.1%
6.8%
Capex IntensityCapex / Revenue
0.4%
11.8%
Cash ConversionOCF / Net Profit
151.48×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$-89.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
VSH
VSH
Q4 25
$-66.9M
$149.4M
Q3 25
$12.1M
$27.6M
Q2 25
$5.4M
$-8.8M
Q1 25
$-16.3M
$16.1M
Q4 24
$34.8M
$67.7M
Q3 24
$50.0M
$50.6M
Q2 24
$44.8M
$-24.7M
Q1 24
$25.9M
$80.2M
Free Cash Flow
CLOV
CLOV
VSH
VSH
Q4 25
$-69.0M
$54.6M
Q3 25
$11.4M
$-24.7M
Q2 25
$4.8M
$-73.4M
Q1 25
$-16.5M
$-45.5M
Q4 24
$33.3M
$-77.2M
Q3 24
$49.6M
$-9.0M
Q2 24
$44.4M
$-87.3M
Q1 24
$25.5M
$27.1M
FCF Margin
CLOV
CLOV
VSH
VSH
Q4 25
-14.1%
6.8%
Q3 25
2.3%
-3.1%
Q2 25
1.0%
-9.6%
Q1 25
-3.6%
-6.4%
Q4 24
9.9%
-10.8%
Q3 24
15.0%
-1.2%
Q2 24
12.5%
-11.8%
Q1 24
7.3%
3.6%
Capex Intensity
CLOV
CLOV
VSH
VSH
Q4 25
0.4%
11.8%
Q3 25
0.1%
6.6%
Q2 25
0.1%
8.5%
Q1 25
0.0%
8.6%
Q4 24
0.5%
20.3%
Q3 24
0.1%
8.1%
Q2 24
0.1%
8.4%
Q1 24
0.1%
7.1%
Cash Conversion
CLOV
CLOV
VSH
VSH
Q4 25
151.48×
Q3 25
Q2 25
-4.39×
Q1 25
Q4 24
Q3 24
Q2 24
6.04×
-1.05×
Q1 24
2.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

VSH
VSH

Resistors Segment$189.4M24%
Diodes Segment$154.2M19%
Capacitors Segment$136.5M17%
Other$126.4M16%
Inductors Segment$92.6M12%
Optoelectronic Components Segment$55.7M7%
EMS Companies$51.6M6%

Related Comparisons